Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

More documents

Recommendations

Info

18 2000 1998 1997 1996 1995 1992 1989 CORPORATE HISTORY EUROPE European operations achieved profitability. Alzheimer’s treatment Aricept is launched in France. Pariet, a proton pump inhibitor, is launched in the United Kingdom and Germany. Alzheimer’s treatment Aricept is launched in the United Kingdom and Germany. Prescription pharmaceutical sales company is established in Germany and France. Prescription pharmaceutical sales company is established in the United Kingdom. Eisai London Research Laboratories are completed. Subsidiaries are established in the United Kingdom and Germany. 2000 1999 1997 1995 1992 1989 1988 1981 UNITED STATES JAPAN ASIA Caring to Help Others. (Caregiver training manual published/distributed) Aciphex, a proton pump inhibitor, is launched. Alzheimer’s treatment Aricept is launched. Construction of process research facility is completed. Construction of facilities for drug formulation research and prescription pharmaceuticals is completed. Prescription pharmaceutical sales company is established. Administrative company is established. Eisai Research Institute of Boston is completed. Clinical research company is established. Chemical and pharmaceutical machinery sales company is established. 2001 2000 1999 1997 1996 1993 1991 1990 1988 1982 1981 1966 1961 1955 1944 1941 1936 Eisai Annual Report 2001 Special R&D incentive system is introduced. Sunplanet Co., Ltd. is established Managerial structure reform implemented. Kawashima Plant received ISO 14001 certification. Alzheimer’s treatment Aricept is launched. Pariet proton pump inhibitor is launched. Internet Home Page established. (http://www.eisai.co.jp) human health care (hhc) corporate message enunciated. First consolidated accounting statement results announced. Sanko Junyaku Co., Ltd. becomes a subsidiary. Yuji Naito becomes Eisai’s chairman, and Haruo Naito assumes the post of president. Construction of the Tsukuba Research Laboratories is completed (Ibaragi Prefecture). Operations commence at the Misato Plant (Saitama Prefecture). Operations commence at the Kawashima Plant (Gifu Prefecture). Founder Toyoji Naito becomes Eisai’s chairman, and Yuji Naito succeeds as Company president. Eisai lists on the Tokyo Stock Exchange and the Osaka Securities Exchange. The Company’s name is changed to Eisai Co., Ltd. Sakuragaoka Research Laboratory and Nihon Eisai Co., Ltd., merge under the name of the latter. Nihon Eisai Co., Ltd., is established in Honjo-machi, Saitama Prefecture. Toyoji Naito establishes a limited partnership called Sakuragaoka Research Laboratory, Eisai’s predecessor. 1998 1997 1996 1995 1991 1989 1987 1979 1974 1970 Alzheimer’s treatment Aricept is launched in Hong Kong and Thailand. Prescription pharmaceutical clinical research company established in the Republic of Korea. Prescription pharmaceutical manufacturing and sales company is set up in China. Prescription sales support company is established in Taiwan. Prescription pharmaceutical sales support company is established in Hong Kong. Prescription pharmaceutical manufacturing and sales company is set up in China. Prescription pharmaceutical sales support company is set up in Thailand. Prescription pharmaceutical sales support company is established in Taiwan. Prescription pharmaceutical sales support and management services company is established in Singapore. Prescription pharmaceutical manufacturing and sales companies are set up in Malaysia and the Philippines. Prescription pharmaceutical manufacturing and sales company is established in Indonesia.
FINANCIAL SECTION Contents 20 Financial Review 24 Consolidated Balance Sheets 26 Consolidated Statements of Income 27 Consolidated Statements of Shareholders’ Equity 28 Consolidated Statements of Cash Flows 29 Notes to Consolidated Financial Statements 39 Independent Auditors’ Report 19
Page 1 and 2: Human Health Care The script for ou
Page 3 and 4: CONSOLIDATED FINANCIAL HIGHLIGHTS E
Page 5 and 6: In Japan, we are proceeding with de
Page 7 and 8: Fiscal 2001 marks the conclusion of
Page 9 and 10: humanity-based sales activities the
Page 11 and 12: Selected Research Candidates (As of
Page 13 and 14: working together to develop antican
Page 15 and 16: REVIEW OF OPERATIONS PHARMACEUTICAL
Page 17 and 18: Consumer Health Care Products The c
Page 19: REINFORCING OUR RELATIONSHIP WITH S
Page 23: Net Income Current income taxes for
Page 26 and 27: 24 CONSOLIDATED FINANCIAL STATEMENT
Page 28 and 29: 26 Consolidated Statements of Incom
Page 30 and 31: 28 Consolidated Statements of Cash
Page 32 and 33: 30 (e) Property, plant and equipmen
Page 34 and 35: 32 Proceeds from sales of available
Page 36 and 37: 34 Note 7. Retirement and Pension P
Page 38 and 39: 36 III. Actual lease payments, Depr
Page 40 and 41: 38 Eisai Annual Report 2001 Million
Page 42 and 43: 40 JAPAN AND OVERSEAS OPERATIONS No
Page 44 and 45: 42 MAJOR PRODUCTS Prescription Phar
Page 46 and 47: 44 CORPORATE INFORMATION (As of Mar

Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?